SRR600724
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.517
- MYOGENESIS+0.446
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.415
- INFLAMMATORY_RESPONSE+0.408
- IL6_JAK_STAT3_SIGNALING+0.403
- COAGULATION+0.365
- APICAL_SURFACE+0.351
- APICAL_JUNCTION+0.348
- KRAS_SIGNALING_DN+0.343
- COMPLEMENT+0.320
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.676
- MYC_TARGETS_V1-0.548
- MYC_TARGETS_V2-0.508
- DNA_REPAIR-0.504
- PROTEIN_SECRETION-0.435
- E2F_TARGETS-0.369
- UNFOLDED_PROTEIN_RESPONSE-0.341
- ADIPOGENESIS-0.340
- MTORC1_SIGNALING-0.298
- G2M_CHECKPOINT-0.296
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1472770 | GTEX | — | 0.982 |
| 2 | SRR1329885 | GTEX | — | 0.955 |
| 3 | BS_ZTWGFWTX | pilocytic astrocytoma | — | 0.946 |
| 4 | SRR598124 | GTEX | — | 0.945 |
| 5 | SRR1489971 | GTEX | — | 0.943 |
| 6 | SRR1352706 | GTEX | — | 0.942 |
| 7 | SRR818469 | GTEX | — | 0.942 |
| 8 | BS_YG0A13JH | pilocytic astrocytoma | — | 0.939 |
| 9 | sclcA055A_S52.txt | — | cohortMD2 | 0.938 |
| 10 | SRR1440082 | GTEX | — | 0.937 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.517 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.446 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.415 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.408 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.403 | Inavolisib | — uncovered |
| COAGULATION | 0.365 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.351 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.348 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.343 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.320 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.317 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.317 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.314 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.295 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.285 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| HYPOXIA | 0.263 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.261 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.256 | Idelalisib | — uncovered |
| APOPTOSIS | 0.198 | Idelalisib | — uncovered |